医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Access2Asia – Australian CRO CPR Pharma Services Provides Bridge for U.S. Biotechs/Pharmas Into Lucrative Asian Clinical Trial Market

2013年04月23日 AM12:40
このエントリーをはてなブックマークに追加


 

ADELAIDE, Australia

The clinical trial market in Asia is booming with an annual 20% growth in clinical trials. US pharmas and biotechs are looking to extend their products’ reach into Asian countries and require access to various ethnicities to fulfil local regulatory requirements for their early phase clinical trial, enabling launch of these products into Asian countries.

Australian-based CRO, CPR Pharma Services (www.cprpharma.com), is launching a unique service targeting U.S.-based companies wanting to access the Asia-Pacific region.

While access to therapeutically naive populations in Asia to conduct late phase studies is not new, CPR is focused on early phase studies, utilising its network of experienced phase 1 units with access to various ethnicities to address this gap in the CRO market for small to medium biotech and pharma.

CPR’s Access2Asia service will be launched at the BIO2013 Conference in Chicago. The service aims to connect U.S. companies with CPR and its network of clinical trial centres to deliver:

  • ethno-bridging studies
  • incorporation of ethnicity arms into Phase 1 trials
  • local management of phase 2a and 2b study support with providers that have the knowledge to navigate the local regulatory environment.

CPR Pharma Services – with last year’s opening of its Singapore office and this month’s launch of its Large Molecule Immunochemistry Analytical Service – is now a regional leader in the provision of clinical trial services, albeit with a core focus in Phase 1 and bridging studies.

BACKGROUND: U.S. companies usually find that there is an inherent risk in accessing sites in the region due to concerns over quality and potential project delays caused by complex local regulatory processes. Australian-based CRO, CPR, is launching a novel service – Access2Asia – aimed at assisting U.S. based pharmas and biotech in navigating the regulatory minefield by supporting all aspects of conducting trials in Asia.

Because of CPR’s extensive network and experience in the region, it has set up Access2Asia – providing U.S. companies with a link to phase 1 units across Asia. Any selected site is then overlayed with CPRs specialist early phase expertise. CPR provides best practice project management, monitoring, data management, quality assurance, pharmacokinetic, bio-statistical, report writing and bio-analytical support services that constitute a high quality clinical trial package.

According to CPR Pharma Services CEO, Jason Valentine, the service allows U.S. companies to not only access “Western-style high quality clinical trials at a fraction of what it costs in the US or Europe,” but also provides access to the booming Asian market. “Asia, and particularly China, has a growing middle class that wants access to pharmaceuticals. In order to access this market Western companies need to trial their drugs in the region. CPR can help these US companies navigate the often complex regulatory systems across Asia,” he said.

For example, Mr Valentine said that gaining approval for a typical Phase 1 trial in China can take up to 20 months. “By using Access2Asia a trial could be started in Australia in as little as 3-6 weeks and by incorporating an ethnicity arm into the study, the process of starting the regulatory process in China can start much sooner, potentially taking two years off of the current timeline for access to the Chinese market,” he said. “We can access Chinese populations in early stage development in Singapore and across Asia, which allows a biotech or pharma to jump start their regulatory process in China.”

For early stage clinical trials CPR can provide the bio-analytical services in its Singapore laboratory as well as in its Adelaide facilities which are FDA-audited. For phase 2a and 2b trials CPR can manage and monitor the trials through its network of hospital sites across Asia as well as deal with local regulatory authorities through their local agents.

“CPR Pharma Services is the only CRO in the region that can offer a quick turnaround in early phase trials in Asia, as well as the opportunity for US companies to have an on-the-ground expert managing all aspects of the trials. At all stages CPR has dedicated senior staff who will oversee each project. ”

FOR FURTHER INFORATION ON HOW CPR IS A KEY PLAYER IN THE ASIA MARKET http://australianetwork.com/focus/s3440444.htm

CONTACT

For further information and to contact Jason Valentine:
For
CPR Pharma Services
Tania Ewing, 614-0837-8422
taniaewing@taniaewing.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • The First China (Chongqing) Selenium Enrichment Industry Development Conference, Organized by the Chongqing Jiangjin Agriculture Commission, Was Held in Jiangjin
  • Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
  • Herbalife Nutrition Hong Kong and Po Leung Kuk Set New World Record in Launching Healthy Active Lifestyle Mobile App
  • Median Technologies Inks a Research Collaboration Agreement for Lung Cancer Screening Programs With Xingtai People’s Hospital, Xingtai City, China
  • Genentech’s HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in Phase III Study in Hemophilia A